List of works - Jan Willem van der Laan

A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies

scientific article published on 11 November 2019

Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells

scientific article published on 19 July 2015

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies

scientific article published on August 2009

Animal models in influenza vaccine testing.

scientific article

Animal-free applications in the development of cell-based therapies

scientific article published on 15 September 2020

Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary

scientific article published on 23 November 2013

Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union

scientific article

Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

scientific article

Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects

scientific article

Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

scientific article published on 26 April 2016

Current status and burning issues in immunotoxicity testing of drugs

scientific article

Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices

scientific article published in July 2005

Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective

scientific article published on 29 October 2019

Human and environmental health challenges for the next decade (2010–2020).

scientific article

Immune function testing of human pharmaceuticals: regulatory overshoot?

scientific article

Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production

scientific article published on 07 February 2017

Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: Report of an EPAA workshop

scientific article published on 15 July 2015

Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model

scientific article

New adjuvanted vaccines in pregnancy: what is known about their safety?

scientific article

Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls ⬇️

scientific article published on 07 April 2020

Oseltamivir and breastfeeding

scientific article

Prediction of carcinogenic potential of chemicals using repeated-dose (13-week) toxicity data

scientific article

Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents

scientific article published on 14 February 2017

Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products

scientific article published on 16 June 2010

Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches ⬇️

scientific article published on March 16, 2012

The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment

scientific article published on November 1, 2010

The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI

scientific article (publication date: February 2004)

Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals

scientific article published on 25 November 2020

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

scientific article

List of works by Jan Willem van der Laan

A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies

Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies

Animal models in influenza vaccine testing.

Animal-free applications in the development of cell-based therapies

Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: a workshop summary

Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union

Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects

Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

Current status and burning issues in immunotoxicity testing of drugs

Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices

Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective

Human and environmental health challenges for the next decade (2010–2020).

Immune function testing of human pharmaceuticals: regulatory overshoot?

Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production

Knowledge sharing to facilitate regulatory decision-making in regard to alternatives to animal testing: Report of an EPAA workshop

Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model

New adjuvanted vaccines in pregnancy: what is known about their safety?

Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls ⬇️

Oseltamivir and breastfeeding

Prediction of carcinogenic potential of chemicals using repeated-dose (13-week) toxicity data

Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents

Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products

Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches ⬇️

The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment

The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI

Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence